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SUMMARY:
Objective: Calprotectin is a calcium binding
heterocomplex protein which appear to have regulatory
functions in the inflammatory process. Epithelial cells which
expressing calprotectin are more resistant to bacterial inva-
sion. In acute phase inflammatory reactions calprotectin is
detectable in elevated levels.
The aim of the present study is to detect the
calprotectin level in saliva in patients with periodontal dis-
ease (chronic and aggressive periodontitis and gingivitis)
and to follow calprotectin level during azithromycin treat-
ment.
Methods and materials: In nine healthy patients
without systemic disease and malignancy whole
unstimulated saliva was investigated.  Salivary calprotectin
levels were measured by enzyme-linked-immunosorbent
using a commercial kit (ELISA Hycult Biotech).
Azithromycin treatment was taken as 500 mg (2 x 250 mg
tabls.) once daily at 10.00 am for 4 consecutive days.
Results: At baseline Day levels of calprotectin
ranged between 1.45 and 2.97; median 2.19. On Day 5 (first
day after azithromycin treatment) the salivary calprotectin
levels decreased in 6 of the patients. The measured values
at Day 10 were more similar to those at Day 5, than those
at Day zero. This was confirmed by the values of the aver-
age median of calprotectin.
Conclusion: We present the first study with the ap-
plication of antibiotic and measurement the calprotectin lev-
els before, during and after azithromycin intake with no side
effects reported.
Measuring calprotectin levels could benefit the moni-
toring of antibiotic treatment efficacy in patients with gin-
givitis and periodontitis
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INTRODUCTION
Calprotectin is a calcium binding heterocomplex pro-
tein (heterodimer of MRP8 and MRP14), which belongs to
the S-100 protein family and is derived predominantly from
neutrophils and monocytes. This putative protective protein
is distributed in myelomonocytic cells, epithelial cells, hu-
man gingival keratinocytes and in various tissues and body
fluids [18]. Calprotectin and its subunits appear to have
regulatory functions in the inflammatory process by regu-
lating the adhesion of myeloid cells to endothelium and ex-
tracellular matrix and activation of effectors cells, direct an-
tibacterial  effects by zinc-capturing, induction of CD 11b
[29]. Epithelial cells which expressing calprotectin are more
resistant to bacterial invasion [7].
In acute phase inflammatory reactions calprotectin is
detectable in elevated amounts that. in some instances cor-
relate to elevated levels of C reactive protein (CRP) or eryth-
rocyte sedimentation rate (ESR) [18].
More recently increased S100A8 and S100A9 lev-
els were also detected in various human cancers presenting
abundant expression in neoplastic tumor cells. The expres-
sion of S100A8 in oral tumorigenesis is helpful only in the
transition from severe dysplastic tissue to cancer [13].
CALPROTECTIN IN SALIVA SAMPLES
The mRNAs of S100A8 and S100A9 are expressed
at minimal levels in the submandibular and parotid glands
of C3H/HeN mice [17].  The levels of calprotectin in 12
healthy adults using different collection devices – parotid
saliva, stimulated whole saliva and “mucosal transudate”
showed a great variation – mean concentrations of 3.2; 22.0
and 40.9 mg/l in the respective oral fluids. These results il-
lustrate the importance of careful sampling procedures [9,
10].
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CALPROTECTIN IN ORAL DISEASE
DENTAL CARIES, GINGIVITIS AND PERI-
ODONTITIS
Toomarian L. et al. have tested 87 children (aged 3-
5 years) with multiple dental caries and cannot determine
if the level of calprotectin in  unstimulated whole saliva is
predictive of severe early-childhood caries [31]. While in
patients with chronic and aggressive periodontitis and gin-
givitis elevated calprotectin levels play a role as a reliable
inflammatory marker in the pathogenesis of periodontal dis-
ease [1, 26].
In other study patients with cyclosporin A (CsA)-in-
duced hyperplasias were estimated and the expression of
calprotectin in gingiva was detected. The results reveal that
several positive S100A8/A9 cells were seen within the con-
nective tissue, whereas in normal gingiva very few positive
S100A8/A9 cells were detected [12].
ORAL CANDIDIASIS AND HIV
The candidacidal calprotectin production, or release,
or both, may be increased in subjects with candidiasis.
Calprotectin is present in saliva at levels which are biologi-
cally active. Calprotectin concentration positively correlate
with intensity of candidal infection [5, 6, 20]. A raised
whole saliva calprotectin levels was found in patients pre-
disposed to oral candidiasis due to HIV infection or
Sjögren’s syndrome and in patients with candidiasis asso-
ciated with various oral disorders (e.g. lichen planus. oral
ulceration). Mean levels of calprotectin were higher in
whole saliva (2 microgram/ml) than in parotid saliva (0.3
microgram/ml) [30].
On the other hand lower calprotectin levels are com-
municated in HIV infection [5, 6]. Those who developed
oral candidiasis had significantly lower parotid calprotectin
levels than those who did not (67 micrograms/l vs. 216
micrograms/l) [3, 23].
SJOGREN SYNDROME
Salivary calprotectin levels correlated with the
plasma calprotectin levels and with several ocular variables
and tend to reflect the local inflammatory activity, provid-
ing a convenient and non-invasive tool for diagnosis [4, 9].
AIM
The aim of the present study is to detect the
calprotectin level in saliva in patients with periodontal dis-
ease (chronic and aggressive periodontitis and gingivitis)
and to follow calprotectin level during azithromycin treat-
ment.
PATIENTS, MATERIALS AND METHODS
Oral health status
Nine general healthy patients without systemic dis-
ease and malignancy (age range 23-52. 7 females and 2
males), underwent dental examination and were screened for
oral lesions and dental problems. Oral-hygiene (assessed by
Debris Index) and gingival status (assessed by papilla bleed-
ing index - PBI) were recorded before treatment with
azithromycin.
We investigated Debris Index (DI) on the representa-
tive teeth (16, 11, 24, 31 – vestibular, 36, 46 - lingual) to
obtain an accurate oral-hygiene status.
Papilla bleeding index of Saxer and Muhleman (PBI)
was used to assess gingival inflammation [28]. The explo-
ration was done lingual in I and III quadrant and vestibular
- in II and IV quadrant. We marked the gingival status in
four stages (Table 1).
Table 1. Degree of PBI (Krasteva A. et al.. 2009)
[21]
Stage PBI Gingival status
1 until  0.5 no gingivitis
2 0.5 – 2 mild gingivitis
3 2 – 3 moderate  gingivitis
4 4 severe gingivitis
Collection of the samples
Whole unstimulated salivary probe was collected into
15ml test tubes for 5 min between 7.30 a.m. and 8.30 a.m.
Subjects were asked to refrain from eating, drinking, smok-
ing for at least 1 hour before saliva collection. The last oral
hygiene procedure had been accomplish in the previous
night, according to Dawes, C and JA Weathrtrll.  [11]. The
specimens (approximately 5 ml) were stored at -20°C and
kept until the analysis.
Saliva was collected 3 times during the study – at
baseline – Day zero, Day 5 (the first day after azithromycin
treatment) and at Day 10.
Azithromycin treatment
Azithromycin treatment was taken as 500 mg (2 x
250 mg tabls.) once daily at 10.00 am for 4 consecutive
days.
METHOD:
Salivary calprotectin levels were measured by en-
zyme-linked-immunosorbent using a commercial kit
(ELISA Hycult Biotech). Two parallel testes were assayed
for each sample. The assays were performed according to
the manifacturer’s instructions.
RESULTS
The data of oral health, saliva calprotectin levels at
baseline (Day zero), at Day 5 and Day 10 after azithromycin
treatment and patients self-assessment (PSA) of gingiva in-
flammation are presented at Table 2.466 http://www.journal-imab-bg.org / J of IMAB. 2014, vol. 20, issue 1/
At baseline Day levels of calprotectin ranged between
1.45 and 2.97; median 2.19 (Table 3). On Day 5 (first day
after azithromycin treatment) the salivary calprotectin levels
decreased in 6 of the patients. Only in 2 patients calprotectin
levels were elevated compared to baseline Day (patient 6 and
7) (Table 2). The measured values at Day 10 were more simi-
lar to those at Day 5, than those at Day zero. This was con-
firmed by the values   of the average median of calprotectin
(Table 3).
Table 3. Salivary calprotectin levels (results are ex-
pressed by Mean and Median)
Salivary calprotectin Day 0 Day 5 Day 10
level (ng/ml)
Mean 2.19 1.81 2.03
Median 2.19 1.86 1.93
Mean and Median values of salivary calprotectin level
at Day zero, Day 5 and Day 10 are presented in Table 3.
Individual Salivary calprotectin  level at Day zero,
Day 5 and Day  10 are prezent in figure 1.
DISCUSSION
Most often calprotectin level is used as a marker and
is detected in domain of gastroenterology. The fecal
calprotectin correlate well with the parameters of disease ac-
tivity in patients with Crohn’s and ulcerative colitis and this
protein serves as a good biomarker and indicator of relapse
of the disease [8, 24, 27]. Also fecal calprotectin may be a
useful marker for application in children during infectious
diarrhea [8].
On the other hand, plasma calprotectin levels have
been shown to be lower (<159 ng/mL) in nonperforated ap-
pendicitis in children compared to perforated appendicitis
[19].
Last year Ortega F. et al. [25] evaluated the serum and
urinary concentrations of calprotectin as markers of insulin
resistance in type 2 diabetes. Circulating calprotectin was sig-
nificantly increased in insulin resistance and type 2 diabe-
tes, and positively associated with HOMA-IR, obesity meas-
ures, inflammatory markers, and parameters of glucose and
lipid metabolism. Similar findings were reported for
Figure 1. Salivary calprotectin individual level at Day zero. Day 5 and Day 10.
Table 2. DI, PBI stage, calprotectin levels of whole saliva at baseline (Day zero), at Day 5 and Day 10 and patients
self-assessment (PSA) of gingiva inflammation after azithromycin treatment.
Patient Sex DI PBIstage Day 0 Day 5 Day 10 PSA after
calprotectin calprotectin calprotectin treatment
(ng/ml) (ng/ml) (ng/ml)
1 M 1.4 2 2.97 1.86 1.93 +++
2 F 2.2 4 2.19 1.74 1.57 ++
3 F 2 4 2.77 2.49 2.50 +++
4 M 1.7 2 3.03 2.29 2.43 +
5 F 1.6 2 1.45 1.29 1.46 +
6 F 2 4 1.58 2.19 1.91 +
7 F 1.6 3 1.50 2.00 2.13 +
8 F 2.2 4 1.86 0.91 1.85 ++
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